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Acyl-CoA thioesterases (Acots) hydrolyze fatty acyl-CoA
esters. Acots in the mitochondrial matrix are poised to miti-
gate -oxidation overload and maintain CoA availability.
Several Acots associate with mitochondria, but whether they
all localize to the matrix, are redundant, or have different
roles is unresolved. Here, we compared the suborganellar
localization, activity, expression, and regulation among mito-
chondrial Acots (Acot2, -7, -9, and -13) in mitochondria from
multiple mouse tissues and from a model of Acot2 depletion.
Acot7, -9, and -13 localized to the matrix, joining Acot2 that
was previously shown to localize there. Mitochondria from
heart, skeletal muscle, brown adipose tissue, and kidney
robustly expressed Acot2, -9, and -13; Acot9 levels were sub-
stantially higher in brown adipose tissue and kidney mito-
chondria, as was activity for C4:0-CoA, a unique Acot9 sub-
strate. In all tissues, Acot2 accounted for about half of the
thioesterase activity for C14:0-CoA and C16:0-CoA. In con-
trast, liver mitochondria from fed and fasted mice expressed
little Acot activity, which was confined to long-chain CoAs
and due mainly to Acot7 and Acot13 activities. Matrix Acots
occupied different functional niches, based on substrate
specificity (Acot9 versus Acot2 and -13) and strong CoA inhi-
bition (Acot7, -9, and -13, but not Acot2). Interpreted in the
context of -oxidation, CoA inhibition would prevent Acot-
mediated suppression of -oxidation, while providing a
release valve when CoA is limiting. In contrast, CoA-insensi-
tive Acot2 could provide a constitutive siphon for long-chain
fatty acyl-CoAs. These results reveal how the family of matrix
Acots can mitigate -oxidation overload and prevent CoA
limitation.
Acyl-CoA thioesterases (Acots)2 hydrolyze acyl-CoA into
CoA and an acyl chain and are classified into two families based
on functional domain. Type I Acots are members of the super-
family of /-hydrolases, are found only in mammals, and have
a high degree of similarity (1). Humans and rodents possess
Type I Acots residing within the cytoplasm (Acot1), mitochon-
dria (Acot2), and peroxisomes (Acot3– 6 in rodents, Acot3– 4
in humans) (1). In contrast, Type II Acots (Acot7–15) share
little similarity beyond a hotdog fold domain (2). Some possess
StAR-related lipid transfer domains (2) or can interact with a
Start domain protein (3) and are found in the cytoplasm
(Acot7–14), mitochondria (Acot7–13 and Acot15), and peroxi-
somes (Acot8) (2). Dual localization is also possible (Acot7, -11,
and -13). Type I and II Acots have a signature substrate speci-
ficity that includes saturated and unsaturated fatty acyl-CoAs
of different chain lengths and, in fewer cases, other CoA esters
(3–5).
Acots are predicted to have high biological relevance because
their substrates, acyl-CoA esters, are also substrates for other
enzymes that serve major metabolic pathways, such as mito-
chondrial -oxidation, and can serve as allosteric or covalent
regulators. In fact, genetic manipulation in mice of Type I or II
Acots is associated with altered phenotypes (2, 7, 8). For exam-
ple, mice with whole-body Acot13 deletion had improved glu-
cose homeostasis on a high-fat diet (9) and improved hepatic
insulin sensitivity in the setting of steatosis (10). Although these
observations suggest that Acot13 loss protects fatty liver from
insulin resistance, it should be noted that Acot13 has dual mito-
chondria-cytosol localization and that the subcompartmental-
ization of Acot13 within mitochondria has not yet been deter-
mined. Thus, it remains unclear whether the response to
Acot13 loss primarily reflects an effect of cytosolic or mito-
chondrial Acot13 loss.
Despite the availability of genetic mouse models and infor-
mation about the Acots, there are basic unexplored questions,
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the answers to which should help provide mechanistic insights
into how Acots alter phenotypes and how to interpret models of
Acot depletion. A fundamental question is whether the Acots
within a cellular compartment occupy functional or tissue-spe-
cific niches or whether, instead, different Acots are largely
redundant, with distinction only in substrate specificity;
whether this is the case has not been considered. Therefore, to
investigate this question, we focused on Acots associated with
mitochondria: Acot2, -7, -9, -11, -13, and -15. In particular,
what is not clear is total Acot activity within mitochondria of
different tissues, the substrate specificity of this activity, and the
mitochondrial Acots that contribute to it in a tissue-specific
manner. Also, the subcompartmentalization within mitochon-
dria is not known for all of the Acots, Finally, regulation is
incompletely understood.
We addressed these questions by evaluating the suborganel-
lar localization of Acot7, -9, and -13. Then, to evaluate tissue
and substrate specificity, we compared four mitochondrial
thioesterases (Acot2, -7, -9, and -13) in terms of activity and
expression, using five mouse tissues. To compare among these
Acots in terms of regulation by metabolic stimuli, effects on
their expression and activity of fasting and potential allosteric
regulators were evaluated in mitochondria from mouse tissues
and recombinant enzymes. A new mouse model of Acot2
depletion allowed us to estimate the quantitative contribution
of Acot2 and Acot13 toward the thioesterase activity for long-
chain fatty acyl-CoA esters. Altogether these data reveal dis-
tinct functional roles for four mitochondrial Acots.
Results
Localization of Acot7, -9, and -13 to the mitochondrial matrix
Subcompartmental localization of Acot2 and Acot15 to the
mitochondrial matrix was demonstrated by immunogold EM
(11, 12), whereas localization of Acot7, -9, and -13 within mito-
chondria has not been determined. Acot7 and -9 each express
an N-terminal mitochondrial targeting sequence (MTS) with
high probability (84 or 93% for Acot7, depending on isoform
(see below); 93% for Acot9; MTS predictions from TargetP).
Acot13, with only a weak TargetP score (30%), has been sug-
gested to reside on the outer surface of the outer mitochondrial
membrane (OMM) (2), but this has not been demonstrated.
Acot11, with only a low-probability MTS, was previously found
localized to the matrix of HEK293T cells (13). Thus, we deter-
mined its mitochondrial localization in mouse tissues. We used
a protease protection approach to analyze the subcompartmen-
talization of Acot7, -9, and -13. Proteolytic destabilization of
the protein following strong membrane disruption by Triton
X-100 served as a positive control. Validated antibodies specif-
ically targeting Tom20, Tim23, and pyruvate dehydrogenase
(PDH) were used to mark the OMM, intermembrane space
(IMS)/inner mitochondrial membrane (IMM), and matrix,
respectively.
We first determined the specificity of the Acot13 antibody
using recombinant Acot13 and liver mitochondria from Acot13
knockout mice (Fig. 1A). Control samples revealed a single
band at 15 kDa; bands near 15 kDa were not detected in the
Acot13 knockout sample unless the membrane was overex-
posed, in which case faint bands were similar across the prote-
ase/detergent conditions (Fig. 1A, right). Thus, the anti-Acot13
antibody is specific for Acot13 in isolated mitochondria.
Next, we exposed isolated mitochondria from three tissues to
two different proteases in the absence or presence of Triton
X-100 or increasing digitonin and evaluated the expression of
Tom20, Tim23, PDH, and Acot13. Tom20 was digested by pro-
tease alone, Tim23 usually required the addition of digitonin for
digestion and was more susceptible to trypsin than to protein-
ase K, and PDH was only digested when Triton X-100 was
added (Fig. 1, A, B, E, and F). In mitochondria from liver, kidney,
and heart with either trypsin or proteinase K, Acot13 was only
digested in the presence of Triton X-100 and thus followed the
pattern of matrix-localized PDH (Fig. 1, B and E).
It was possible that some Acot13 was loosely associated with
the outer surface of the OMM but was dislodged during tissue
homogenization. We reasoned that if this occurred, the super-
natant fraction of the high-speed spin used to pellet mitochon-
dria would contain a substantial amount of Acot13. Indeed,
Acot13 was previously found in the supernatant fraction, and it
was concluded that it can reside in the cytoplasm as well as be
associated with mitochondria (3). To estimate the fraction of
Acot13 in the cytoplasm (or loosely bound to the OMM),
immunoblot analysis was conducted on different fractions
from the liver and heart mitochondria isolations (Fig. 1C).
Compared with the amount of Acot13 detected in the total
homogenate, 5 times more was found in the high-speed pellet
from liver and 2 times more was found in the high-speed
pellet from heart. In contrast, band intensity in the supernatant
of both tissues was less than half of that in the total homogenate.
For the heart, this pattern of distribution of Acot13 between
pellet and supernatant was similar to that for three IMM pro-
teins (Complex I 37-kDa subunit, Complex II SDHA subunit,
Complex III Core I subunit), raising the possibility that, in the
heart, Acot13 in the supernatant reflects co-contaminating
mitochondrial proteins rather than a cytoplasmic or OMM-
associated fraction.
The situation for the liver was different (Fig. 1C). Acot13 in
the supernatant as a fraction of the total liver homogenate was
substantially higher than that for any of the three IMM proteins
(0.4 for Acot13 versus 0.1– 0.2 for C-I, SDHA, and C-III), sug-
gesting that, in the liver, some Acot13 was present in the cyto-
plasm and/or very loosely associated with the OMM. However,
for both liver and heart, the majority of Acot13 was present in
the high-speed pellet and thus would situate a substantial
amount of Acot13 within the matrix.
Analysis using MTS prediction algorithms indicated an MTS
probability of mouse Acot13 of 30% (TargetP) or 39% (Mito-
Prot II algorithm). MTS prediction for human Acot13 isoform
1 was higher (52%, TargetP; 63%, MitoProt II) and was lower
for human Acot13 isoform 2 (12% using TargetP; 50%, Mito-
Prot II). We searched for an internal targeting sequence (14) by
sequentially shortening the amino acid sequence by 1 amino
acid starting at the N-terminal; there was no MTS greater than
20% anywhere within the protein.
Perusing MitoCarta2.0 revealed bona fide matrix proteins
having MTS predictions 30% (e.g. ribosomal proteins
MRPS22, MRPL42, and MRPL48). This, together with matrix
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localization of Acot13 despite its low MTS prediction score
prompted us to systematically determine the reliability of MTS
prediction algorithms using a recently published high-confi-
dence mitochondrial yeast proteome (15). Using the TargetP,
MitoFates, and MitoProt II algorithms and a cutoff MTS prob-
ability of 65%, the false negative rate (high-confidence mito-
chondrial proteins with MTS 65%) was 60, 56, and 38% for
each algorithm, respectively. The false positive rate (high-con-
fidence, nonmitochondrial protein with MTS 65%) was 4, 1,
and 14% for each algorithm, respectively. Furthermore, plotting
the MTS scores for high-confidence mitochondrial and nonmi-
tochondrial proteins revealed many high-confidence mito-
chondrial proteins with MTS scores 25% (Fig. 1D). We also
analyzed the human and mouse MitoCarta2.0 databases (16)
for proteins annotated as “Apex_matrix”; 6% of these proteins
had a low MTS score (category “5” in MitoCarta) or were cate-
gorized as having no MTS (“no score” in MitoCarta). These
analyses indicate that MTS scores 65% predict mitochondrial
proteins well, whereas a low MTS score is unreliable as evi-
dence that a protein is nonmitochondrial. This can, in part,
occur as some mitochondrial proteins carry targeting signals
other than a classical N-terminal MTS. Whereas these are char-
acterized for some classes of proteins (e.g. substrates of TIM22
or MIA pathways), targeting information for many of these pro-
teins is unknown.
Localization of Acot9 was tested in kidney and heart mito-
chondria, as it is robustly expressed (5) (Fig. 2). A custom anti-
body tested in mouse tissues (5) was used and shows a single
band of 50 kDa, with minimal or no additional bands. In both
kidney and heart mitochondria, the 50 kDa band disappeared
only after adding trypsin plus Triton X-100, as was found for
matrix PDH (Fig. 1E).
Acot7 has three transcripts annotated in NCBI. Transcripts 1
and 3 have a strongly predicted MTS (84 and 93%, respectively,
using TargetP), whereas prediction for transcript 2 is only 11%.
The custom anti-Acot7 antibody was validated in tissues from
Acot7 knockout mice (17). Using this antibody, we found that
the predominant band is at 37 kDa (cleaved N-terminal
sequence in isoforms 1 and 3). Occasional faint bands appeared
at 42 kDa (representing the unprocessed protein) and 50
kDa. We found that liver mitochondria clearly expresses the 37
kDa band, whereas signals were much weaker or barely detect-
able in mitochondria isolated from other tissues (see Fig. 2A).
Thus, we selected only liver mitochondria for further protease
experiments. The 37 kDa band recognized by the anti-Acot7
antibody was destabilized only when the sample was treated
with protease plus Triton X-100 (Fig. 1F) and thus followed the
same pattern as matrix-localized PDH.
Finally, using an antibody against Acot11 validated in knock-
out mouse tissue (18), a band was observed in the high-speed
pellet fraction in the brown adipose tissue (BAT) preparation
but not in the high-speed pellets from heart, skeletal muscle,
liver, or kidney (Fig. 1G).
Fig. 1H summarizes the localization of the mitochondrial
Acots empirically determined here and in previous studies.
Tissue-specific Acot expression and thioesterase activity
The above observations indicate that Acot13 joins Acot2, -7,
-9, and -15 as Acots that localize to the matrix, raising the pos-
sibility of redundancy among the five mitochondrial Acots. Tis-
sue-specific expression would be one way that these Acots are
not redundant. Here we compared Acot protein expression and
thioesterase activity among mitochondria from five tissues.
Two of these, liver and heart, have already been associated with
mitochondrial Acot expression (4, 19–23). Three other tissues,
skeletal muscle, BAT, and kidney, are known to express mito-
chondrial Acots (5, 17, 22, 24, 25) but have been relatively less
studied.
There were several methodological considerations for the
immunoblotting studies. First, concerning the antibodies,
those against Acot2, -7, and -13 have been tested in knockout
mice (12, 17, 26) (this work), whereas there is no reliable com-
mercially available antibody against Acot15. Second, mito-
chondrial fractions were largely devoid of cytoplasmic proteins
(e.g. see Fig. 1C). Third, for normalization, samples were probed
for three different proteins: the 37-kDa subunit of C-I, SDHA,
and cytochrome c (Cyto c). The average of the normalized val-
ues was used. A new aliquot of the Acot2 antibody that was used
for BAT mitochondria generated multiple bands; for interpre-
tation, these immunoblots included samples from Acot2
whole-body knockout mice (Acot2/; see Fig. 3B). BAT was
excluded from the Acot7 analysis because the Acot7 antibody
generated multiple bands centered around 37 kDa.
Heart, skeletal muscle, BAT, and kidney mitochondria all
robustly expressed Acot2 and Acot13 (Fig. 2A). Skeletal muscle,
BAT, and kidney mitochondria also expressed Acot9, and heart
Figure 1. Acot7, -9, and -13 localize to the mitochondrial matrix. Protease protection experiments (A, B, E, and F) determined the submitochondrial location
of Acot7, -9, and -13 using trypsin or proteinase K (PK), and increasing digitonin (Dig) concentration. Triton X-100 plus protease served as a positive control for
protease sensitivity. Tom20 marked the OMM, Tim23 marked the IMS/IMM, and PDH marked the matrix. In all panels, mitochondria were isolated from the
indicated mouse tissue. A, recombinant Acot13 and liver mitochondria from Acot13 knockout (ko/ko) and WT (wt) mice were used to determine the specificity
of the anti-Acot13 antibody. Note that the molecular weight of recombinant Acot13 is slightly higher than endogenous Acot13 due to the presence of a His10
tag on recombinant Acot13. B, protease protection experiment to determine the subcompartmentalization of Acot13, using the mitochondrial fraction of a
liver fractionation. C, distribution of Acot13 between mitochondria (pellet) and nonmitochondrial fraction. Subunits of electron transport chain Complex I, II,
and III (C - I, SDHA, and C - III) were used to mark mitochondria. Glyceraldehyde 3-phosphate dehydrogenase (GADPH) marked the cytoplasm. Values were
calculated by expressing supernatant (Sup) and “pellet” as a fraction of the post-nuclear (PN) supernatant (PN Sup  1, not shown). D, MTS prediction accuracy
by three algorithms using data from a high-confidence mitochondrial proteome from yeast (15). Yeast proteins were classified as mitochondrial (Yes mito) or
nonmitochondrial (Not mito) according to Ref. 15. The amino acid sequences of the complete proteome of reference strain S288C were retrieved from the
Saccharomyces Genome Database and subjected to MTS prediction using the TargetP, MitoProt II, and MitoFates algorithms. The resulting prediction scores
for mitochondrial localization are plotted as points for each individual protein. Blue lines mark the MTS prediction for Acot13. E and F, protease protection
experiment to determine the subcompartmentalization of Acot9 (E) and Acot7 (F) using the mitochondrial fraction of kidney, heart, and liver fractionations. G,
Acot11 is not widely expressed in mitochondria from various tissues. H, heart; K, kidney; SKM, skeletal muscle; L, liver. H, summary of mitochondrial Acots,
likelihood of an MTS (calculated using TargetP algorithm), whether or not the Acot is annotated in MitoCarta 2.0 (16) as a mitochondrial protein, the evidence
for localization within mitochondria, and whether or not the Acot is dual-localized. A, B, C, E, F, and G, amounts loaded are 5 g of mitochondria to detect
Acot13, 30 g of mitochondria to detect Acot9, 20 g of mitochondria to detect Acot7, and 10 ng of recombinant Acot13
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did as well but at a level that was 40 –50% of the activity in the
other tissues. Acot7 was low in mitochondria from these tis-
sues. Liver mitochondria expressed Acot7 and Acot13, but very
little Acot2 and Acot9. Thus, mitochondria from skeletal mus-
cle, BAT, kidney, and heart robustly expressed three different
matrix Acots (Acot2, Acot9, and Acot13), whereas liver mito-
chondria show lower Acot expression, mainly contributed by
Acot13 and Acot7.
Glycolytic and oxidative muscles express a different abun-
dance of proteins mediating metabolism and signaling, includ-
Figure 2. Tissue-specific localization of mitochondrial Acots. A, immunoblot analysis using isolated mitochondria. For the quantification, normalization
was to Complex I, Complex II (SDHA), and Cyto c; normalizations to each of the latter were averaged and then expressed relative to that for kidney or heart
mitochondria (equal to 1.0). The table shows p values, one-way ANOVA, and Tukey post hoc tests. H, heart mitochondria; K, kidney mitochondria; S, skeletal
muscle mitochondria; L, liver mitochondria; NS, not significant. The antibody against Acot2 used with the BAT samples yielded nonspecific bands slightly below
the Acot2 band. To interpret the Acot2 bands, mitochondria from Acot2/ tissues were run in parallel. Only the upper band (arrow) of the WT samples was
used for quantification. The Acot7 signal was not evaluated in BAT because the antibody yielded many nonspecific bands. Values are mean  S.E. (error bars),
n  5– 6. The amount of protein loaded was 30 g for Acot2 and Acot9, 40 g for Acot7, 5 g for Acot13, Complex I, SDHA, and Cyto c. B, immunoblot analysis
using muscle lysates (40 g). The quantification shows mean  S.E. (error bars), n  3, Acot values expressed relative to different abundant mitochondrial
proteins (Complex I, SDHA, or Complex III). Statistical analysis was by one-way ANOVA and Tukey post hoc pairwise comparisons (p values refer to Tukey test):
* and **, p  0.01 and 0.05, respectively, versus all other muscles. C, mRNA expression by quantitative PCR. Values are mean  S.E., n  5– 6. Statistical analysis
was by one-way ANOVA and Tukey post hoc pairwise comparisons (p values refer to Tukey test): $, p  0.05, heart versus kidney, skeletal muscle (Skm), and liver;
$$, p  0.01 BAT versus kidney, skeletal muscle, and liver; *** and **, p  0.001 and p  0.003, respectively, BAT versus all other tissues; ###, p  0.001, heart versus
all other tissues.
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ing proteins encoded by peroxisomal proliferator-activated
receptor (PPAR)-induced genes. Because some Acots are
induced by PPAR agonists (3, 11, 19, 21, 22, 27–29), we tested
mitochondrial Acot expression in different skeletal muscles,
namely in soleus (highly oxidative), white quadriceps (glyco-
lytic), and the redder portion of gastrocnemius (mixed oxida-
tive). Lysates were used because mitochondria cannot be reli-
ably isolated from small pieces of mouse skeletal muscle.
Because the Acot2 antibody likely also recognizes cytoplasmic
Acot1, and showed multiple bands in muscle lysates, Acot
abundance in different muscles was determined for Acot9 and
Acot13 but not Acot2. Acot9 showed relatively higher expres-
sion in white gastrocnemius compared with oxidative muscles
and heart (Fig. 2B). In contrast, Acot13 expression was similar
in glycolytic and oxidative muscles (Fig. 2B).
Although a tissue comparison of Acot mRNA was recently
published (17), as a complement to our data set, we evaluated
mRNA levels in the five tissues studied here (Fig. 2C). Data
generally agree with published values. Notably, Acot2, Acot7,
and Acot13 mRNA were robust in all tissues except the liver.
To further understand the relative contribution of different
matrix Acots to a tissue’s thioesterase activity, we measured
thioesterase activity using a range of acyl-CoA species that cov-
ers the substrate specificity of the matrix Acots. Activity mea-
surements also allow quantitative comparisons among sub-
strates within a tissue.
Thioesterase activity for C4:0-CoA was by far the highest, at
10 –20 nmol/min/mg versus 1– 6 nmol/min/mg for the other
substrates (Fig. 3A) (in all cases, unless otherwise stated, mg
refers to mg of mitochondrial protein). BAT and kidney mito-
chondria showed the highest activity for C4:0-CoA (20 nmol/
min/mg), followed by heart and skeletal muscle mitochondria
(10 nmol/min/mg). Activity toward C4:0 was very low in liver
mitochondria. This pattern of activity for C4:0-CoA is consis-
tent with the Acot9 protein abundance in these tissues and the
fact that the only Acot known to show activity for C4:0-CoA is
Acot9 (3, 5, 12, 30).
Thioesterase activity for C8:0-CoA was lower (2– 4 nmol/
min/mg) than for C4:0-CoA but showed a similar tissue distri-
bution as for C4:0, including minimal activity in liver mito-
chondria (Fig. 3A). As for C4:0-CoA, C8:0-CoA is a good
substrate for Acot9 (5) but not Acot2, -13, or -15 (3, 11, 12).
Thus, thioesterase activity toward C4:0- and C8:0-CoA can be
used as a surrogate for Acot9 expression in BAT, kidney, heart,
and skeletal muscle.
Thioesterase activity for C14:0-, C16:0-, and C16:1-CoA was
2– 6 nmol/min/mg in mitochondria from all tissues, with activ-
ity in liver mitochondria at the lower end of the range and in
heart at the higher end (Fig. 3A). This pattern of activity among
tissues generally matched protein levels for Acot2 and Acot13,
which both have C14:0-, C16:0-, and C16:1-CoA as major sub-
strates. Acot9 is reported to have substantial activity for C14:0-
CoA (but not for C16:0- or C16:1-CoA) (5). However, activity
for C14:0-CoA was not higher in BAT and kidney mitochon-
dria, which expressed the most Acot9. Similarly, C14:0- and
C16:0-CoA are good substrates for Acot7 (30), yet liver mito-
chondria, with the most Acot7 among the five tissues, had low
activity toward these substrates. Thus, Acot7 and Acot9 may
have different substrate selectivity in their native context.
Finally, we tested thioesterase activity toward C18:1-CoA
and C18:3-CoA, major substrates for Acot15 but poor sub-
strates for the other mitochondrial Acots (5, 12, 28, 30). In
mitochondria from all tissues, activity for either substrate was
1 nmol/min/mg (Fig. 3A). Thus, the contribution of Acot15
to matrix thioesterase activity is likely to be minor.
We questioned how much thioesterase activity within mito-
chondria is attributable to each Acot. Here, we used a new
mouse model of Acot2 loss to estimate the contribution of
Acot2 to the total mitochondrial thioesterase activity. We gen-
erated mice with floxed Acot2 alleles (Acot2fl/fl), from which
germ line whole-body Acot2 knockout (Acot2/) mice were
generated (Fig. 3B). Mitochondria from these mice were used to
estimate Acot2-specific activity. First, the possibility of com-
pensatory up-regulation of other mitochondrial Acots was con-
sidered. Acot2/ mice had higher mRNA for Acot9 in liver
and Acot13 in kidney and skeletal muscle (Fig. 3C), but protein
levels were unchanged (Fig. 3D). Acot15 mRNA was higher in
all Acot2/ tissues (Fig. 3C), but the protein is unlikely to be
higher because thioesterase activity for its major substrate, C18:
3-CoA, was unchanged (Fig. 3E).
Fig. 3E depicts thioesterase activity in five tissues from
Acot2/ mice. Acot2-specific activity was estimated as the
difference in the average activity from mitochondria from con-
trol and Acot2/ mice (Fig. 3F). Values for C4:0- and C8:0-
CoA in the Acot2/ samples were within the variability of the
control samples (Fig. 3A). Thus, Acot2/ samples only
showed activity for C14:0-, C16:0-, and C16:1-CoA, and very
low activity for C18:3-CoA, consistent with the expected sub-
strate specificity for Acot2 (11). Acot2-specific thioesterase
activity for these substrates in heart, skeletal muscle, kidney,
and BAT was 2–5 nmol/min/mg. Liver mitochondria expressed
very little Acot2-specific activity.
In the Acot2/ samples, activity toward C16:0- and C16:1-
CoA in heart, skeletal muscle, BAT, and kidney likely reflects
activity of only Acot13 because Acot7 is minimally expressed in
those tissues and Acot9 has minimal activity for those sub-
Figure 3. Tissue-specific mitochondrial thioesterase activity and contribution of Acot2. A, thioesterase activity in mitochondria from mouse tissues (skm,
skeletal muscle) for a range of acyl-CoAs. Statistical analysis was by one-way ANOVA, Tukey post hoc tests. **, p  0.05, liver versus all other organs; *, p  0.05
versus heart and liver; #, p  0.05, liver versus skeletal muscle, heart, and kidney; $, p  0.05, skeletal muscle and liver versus BAT and kidney. Values are mean 
S.E. (error bars); n  6 – 8. B, Acot2 whole-body knockout mouse (Acot2/) model generated by crossing mice with floxed Acot2 alleles (fl/fl) with mice
expressing Cre recombinase driven by the eIIa promoter. Knockout was validated by PCR and Western blotting (wb) analysis using isolated mitochondria.
Arrow, faint Acot2 band in fl/fl liver mitochondria. C and D, evaluation of possible compensatory changes (mRNA (C) and mitochondrial protein (D)) in the
expression of other mitochondrial Acots in Acot2/ mice. The amount of protein loaded was 30 g for Acot2 and Acot9, 40 g for Acot7, and 5 g for Acot13
and Complex I (C - I). Statistical analysis in C was by t test (levels in Acot2/ versus floxed control mice): *, **, and ***, p  0.05, p  0.03, and p  0.01,
respectively. E, thioesterase activity in mitochondria from the indicated tissues harvested from Acot2/ mice. Values are mean  S.E.; n  4 –5. F, Acot2-
specific thioesterase activity calculated by subtracting activity measured in Acot2/ mitochondria (E) from activity measured in mitochondria from floxed
mice (A). Error bars in F, Gaussian error propagation (calculated as the square root of the sum of the variances).
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strates. Acot13 activity can be estimated as 2–3 nmol/min/mg
toward C16:1-CoA and 1 nmol/min/mg toward C16:0-CoA
except in BAT, where it is 3 nmol/min/mg.
In summary, the highest thioesterase activity in mitochon-
dria is toward C4:0-CoA, catalyzed by Acot9, and is 3–10 times
higher than activity toward C14:0-, C16:0-, and C16:1-CoA,
which are catalyzed to a similar extent by Acot2 and Acot13.
Activity toward C18:1- and C18:3-CoA is very low, suggesting
only a minor contribution of Acot15 to matrix thioesterase
activity. Finally, BAT, kidney, heart, and, skeletal muscle mito-
chondria expressed far more thioesterase activity than liver
mitochondria.
Regulation of matrix Acots
Some Acots are transcriptionally regulated by PPAR ago-
nists, and nutritional stimuli such as high-fat feeding and fast-
ing studies have mainly shown this at the mRNA level (3, 19, 21,
29, 31), but some also at the protein level (11, 21, 27, 32). Fur-
thermore, Acot2 mRNA in the mouse heart oscillates with the
time of day, with the lowest expression near the end of the light
phase (29). Thus, mitochondrial Acot activity may be more
prevalent at certain times of the day due to time-dependent
effects on gene regulation. To test this, we measured Acot pro-
tein abundance and activity in mitochondria from liver, skeletal
muscle, and kidney from overnight fasted mice and compared it
with that from mice 2 h before the end of the light phase.
With fasting, Acot2 protein rose by 20%, whereas protein
levels of Acot9, Acot7, and Acot13 did not change (Fig. 4, A and
B). Likewise, thioesterase activity in mitochondria from fasted
mice was only increased for Acot2 substrates (Fig. 4C). Thus,
although some Acots are readily induced by PPAR agonists and
high-fat feeding, induction by physiological stimuli appears to
be milder.
Beyond transcriptional regulation, there is some information
on allosteric and other regulation of the Acots. However, this
information is incomplete and does not include potential allos-
teric regulators of Acot2 or of Acot13 that would be relevant for
its matrix localization. The activity of Acot1 (98% identical to
Acot2 at the amino acid level (1)) was reported to not be regu-
lated by CoA, although data were not shown (33). Using liver
mitochondria overexpressing Acot2 (23) and hydrolyzing C14:
0-CoA, Acot2 activity was insensitive to CoA up to 200 M (Fig.
5, A and B). Because Acot9 was strongly inhibited by NADH
(IC50 of 300 M for C3:0-CoA and 500 M for C14:0-CoA)
(5), we tested the sensitivity of Acot2 and -13 activity to NADH
and NAD and found that neither Acot2 nor Acot13 was sub-
stantially changed by 1 mM NADH or NAD (Fig. 5, A and B).
We also tested for sensitivity toward ADP and ATP and found
that Acot2 and Acot13 activity was inhibited by 20% by 10 mM
ADP or ATP (Fig. 5, A and B).
CoA inhibits Acot7 and Acot9 (5, 34). For Acot9, the [CoA]
at which activity was 50% inhibited (IC50) was 100 M with
C3:0-CoA and 150 M with C14:0-CoA. Although it is diffi-
Figure 4. Fasting induces only small changes in mitochondrial Acot protein and thioesterase activity. Protein levels (A and B) and thioesterase activity (C)
of Acots in mitochondria isolated from the indicated tissues harvested from overnight fasted mice (9 a.m. tissue harvest) and ad libitum fed mice (5 p.m.
tissue harvest). Harvest times matched points of highest and lowest Acot2 mRNA expression (29). In A and B, values are mean  S.E. (error bars); n 
4 –5/condition. *, p  0.05; **, p  0.02, unpaired t test. In A, the amount of protein loaded was 30 g for Acot2 and Acot9, 40 g for Acot7, and 5 g for Acot13
and SDHA.
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cult to accurately ascertain [CoA] within the matrix, inhibition
of Acot activity by 100 –150 M CoA is likely to be physiologi-
cally relevant. To determine whether Acot13 is inhibited by
CoA, we used recombinant mouse Acot13 (3); activity toward
C14:0-CoA was strongly inhibited by CoA with an IC50 of 35
M (Fig. 5B).
StarD2 (also known as phosphatidylcholine transfer protein)
interacts with Acot13 (35). Recombinant StarD2 approximately
doubled the Vmax of recombinant Acot13 (3, 35); thus, StarD2
could be considered as a regulator of Acot13. Because a signif-
icant fraction of Acot13 is in the matrix, we asked whether
StarD2 was also present. Using the protease protection ap-
proach, StarD2 was associated with mitochondria (Fig. 6A), as
reported (3), and also with the post-nuclear supernatant frac-
tion of the 8000 	 g spin, consistent with its presence also in the
cytosol (3). Mitochondria-associated StarD2 was fully cleaved
by trypsin alone, analogous to Tom20 (Fig. 6A). Trypsin also
cleaved Tim23, and we had trouble obtaining conditions distin-
guishing Tim23 and Tom20. Thus, StarD2 localizes to the
OMM, IMM, and/or intermembrane space. If it is in the matrix,
its abundance is very low. Thus, the majority of matrix Acot13
would not be influenced by StarD2.
The interaction of StarD2 with Acot13 in the liver was shown
to increase during the early phase of refeeding after mice were
fasted overnight (8). Moreover, StarD2 localization to mito-
chondria increased with PPAR agonist treatment (36). Thus, we
asked whether the fraction of Acot13 available to be regulated
by StarD2 depends on nutrient availability. We questioned
whether fasting and refeeding are associated with a redistribu-
tion of Acot13 away from mitochondria, whether Acot13 asso-
ciates with the OMM during refeeding, and whether the asso-
ciation of StarD2 with mitochondria changes. Thus, we
fractioned the liver from fed and overnight fasted mice, and
from mice fasted and then refed for 2 or 5 h, and then performed
protease protection experiments on the 8000 	 g pellet. Fasting
did not influence the amount of StarD2 associated with mitochon-
dria (Fig. 6B). Comparing fasting with refeeding, the amount of
StarD2 or Acot13 associated with mitochondria was similar (Fig.
6C), as was the localization of mitochondrial Acot13 to the matrix
and StarD2 to the OMM/IMS/IMM (Fig. 6D).
Discussion
Here, we undertook a comparison of mitochondrial thioes-
terases, in terms of activity, expression level, and regulation,
among mitochondria from different tissues to provide insight
into why there are so many matrix-localized Acots. It was
already suggested that several matrix Acots co-existed, some
with an overlapping tissue expression and substrate specificity,
raising the question of whether some matrix Acots are redun-
dant. Alternatively, different matrix Acots could have unique
roles, defined by tissue specificity and/or regulation. These are
important questions, as matrix Acots are poised to regulate
Figure 5. Distinct allosteric regulation of mitochondrial Acots. A, allosteric regulation of Acot2. Shown is Acot2-specific thioesterase activity toward 5 and
10 M C16:0-CoA (palmitoyl-CoA: PCoA) in liver mitochondria without and with Acot2 overexpression. Values are mean  S.E. (error bars); n  4 – 6. *, p  0.02;
***, p  0.001; both p values are 10 mM versus 0 mM ADP or ATP and 10 mM versus 2 mM ADP or ATP; two-way ANOVA, Tukey post hoc tests. B, allosteric regulation
of recombinant Acot13, using C14:0-CoA (10 M) as the substrate. Values are mean  S.E.; n  4 technical replicates.
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mitochondrial -oxidation, which is susceptible to overload
with consequences for -oxidation itself (6, 37), for other
matrix pathways, and ultimately for other aspects of cell func-
tion. Thus, understanding the characteristics of Acots, both
individually and as a group, should provide insight into how
Acots influence -oxidation and how best to study the matrix
Acots. The current study sought to fill key gaps and provide
easy comparisons among thioesterase activities and expression
of Acots in mitochondria from several mouse tissues.
The main findings are summarized in Fig. 7. Our study is the
first to establish that Acot7, Acot9, and Acot13 localize to the
matrix. This finding is important in light of the existing data on
the biological role of Acot13 (2, 8). Second, all mitochondria
surveyed, except from liver, robustly expressed Acot2, Acot9,
and Acot13. Liver, in contrast, expressed some Acot7 and
Acot13 and low levels of Acot2. This pattern of mitochondrial
Acot expression and activity across tissues highlights the
potential importance of Acots in tissues such as kidney, skeletal
muscle, and heart, where Acots are understudied. Third, Acot9
protein was previously shown to be very low in skeletal muscle,
with a band shifted higher in molecular weight, and to be unde-
tectable in heart (5). Here we show substantial thioesterase
activity for C4:0-CoA in heart and skeletal muscle mitochon-
dria. Acot9 is the only matrix Acot that hydrolyzes C4:0-CoA,
and skeletal muscle and heart expressed Acot9 at a molecular
weight similar to that in BAT and kidney (5) (this work). Thus,
Acot9 is expressed in heart and even more so in glycolytic skel-
etal muscle. Fourth, the most important source of regulation of
the Acots, specifically Type II Acots, was from CoA. In contrast,
Acot2, a Type I Acot, was not regulated by CoA; nor was it
substantially regulated by the potential allosteric regulators we
tested, raising the possibility that Acot2 is constitutively active,
but at a low level based on the estimate obtained from Acot2/
mitochondria. Altogether, these observations reveal that,
despite potential redundancy due to some overlap in tissue
expression and substrate specificity, different matrix Acots may
occupy different functional roles determined mainly by regula-
tion (Acot7, -9, and -13 versus Acot2) and substrate specificity
(Acot9 versus Acot2 and -13).
Our study also highlights that, in contrast to the robust up-
regulation of Acot mRNA by pharmacologic induction of
PPARs (3, 19, 21, 29, 31), fasting, a physiological stimulus of
PPARs, had a minimal impact on mitochondrial Acot expres-
sion or activity. Thus, despite pharmacological approaches sug-
gesting PPAR induction of Acot mRNA as an important means
of regulating Acots, regulation by CoA of Type II Acots may be
quantitatively the most important physiological means of reg-
ulating the activity of matrix Acots (Type II only).
Finally, because StarD2 can increase Acot13 activity (3), we
determined whether StarD2 could regulate matrix-localized
Acot13. However, our findings suggest that matrix-localized
Acot13 would be minimally or not influenced by StarD2 under
a number of physiological conditions. These results are note-
worthy because the amount of Acot13 that associates with
Figure 6. Co-localization of Acot13 and its regulator StarD2 is minimal for the matrix Acot13 pool, even after major nutrient perturbations. A, liver
fractionation and protease protection experiment on the 8000 	 g pellet fraction of liver from a fed mouse. GADPH was used as a cytoplasmic (cyto) marker.
Sup., supernatant. B, mitochondrial fraction from liver harvested from ad libitum fed or overnight fasted mice. Bar chart, mean  S.E. (error bars), n 
5/condition; no significant difference (unpaired t test). C, mitochondrial (8000 	 g pellet) fraction from liver harvested from mice fasted overnight or fasted
overnight and then refed for 2 or 5 h; D, protease protection experiments from these mitochondria. A and D, further details about protease protection
experiments are available in the legend to Fig. 1. In all panels, 10 g of protein were loaded.
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StarD2 was higher in the liver of mice that were refed after an
overnight fast (8). Our findings suggest that this greater associ-
ation of Acot13 and StarD2 involved the cytoplasmic pools of
these proteins, whereas the matrix pool of Acot13 was unper-
turbed. More generally, our data indicate that there are two
pools of Acot13, namely a cytoplasmic pool that can interact
variably with StarD2 and a matrix pool that is largely seques-
tered from StarD2.
Acot13 localizes to the mitochondrial matrix
Using two different proteases and mitochondria from three
different tissues, we provide evidence that Acot13 localizes to
the mitochondrial matrix, even though the prediction of an
N-terminal MTS or an internal targeting sequence is low
(30%).
Two studies document that the acetylated proteome of
mouse liver mitochondria showed a significant acetylation of
residue Lys-13 of Acot13 that depended on the matrix deacety-
lase Sirt3 (38, 39). Sirt3-dependent acetylation of Acot13 was
also observed in heart mitochondria, although the specific res-
idue was not indicated (40). Further analysis of these acetylated
proteomes revealed that established OMM proteins with acety-
lated lysines did not have any that were Sirt3-dependent. These
observations further support the matrix localization of Acot13.
Regulation of matrix Acots
We found Acot13 to be strongly inhibited by CoA (Fig. 5), as
reported for Acot7 and Acot9 (5, 34). Although it is difficult to
measure [CoA] in the matrix, the [CoA] that inhibits Acot9
(IC50  100 M) and Acot13 (IC50 35 M) is expected to fall
within the physiological range of [CoA], positioning these
Acots as safety valves gated by CoA. Heart, skeletal muscle,
kidney, and BAT mitochondria substantially expressed Acot9
and Acot13 (Fig. 3), which, together, have a substrate specificity
covering short- to long-chain acyl-CoAs. Thus, the ability to
expand the capacity of thioesterase activity in response to low
[CoA] would apply across a wide range of fatty acyl-CoAs in
these tissues. In contrast, liver mitochondria expressed little
Acot9. Thus, CoA gating would only occur in liver mitochon-
dria for long-chain acyl-CoAs, via Acot13.
Acot2 activity was only slightly inhibited by ADP and ATP
and was unaffected by the other potential allosteric regulators
we tested, including CoA. It is possible that acetylation regu-
lates Acot2 activity because two acetylated lysine residues
appeared in mitochondrial protein acetylation screens (38, 39).
Based on the crystal structure of human Acot2 (41), one of these
lysines (Lys-345 in human Acot2) is near the active site but
pointed away from it. The other lysine (Lys-104 in human
Acot2) is in a loop that could serve as a flap over the active site;
because acetylation imparts a negative charge, and CoA is neg-
atively charged, Lys-104 acetylation might alter substrate bind-
ing. However, the acetylation state of both lysine residues was
insensitive to Sirt3 (38, 39).
Considerations for evaluating the role of matrix Acots in
-oxidation
For all matrix Acots, the obvious competing pathway is -ox-
idation because the fatty acyl-CoA dehydrogenases could com-
pete directly for fatty acyl-CoA substrates. Competition would
be on the basis of substrate specificity and Km; Km values for
Acot2 and -13 are similar to those of the long-chain acyl-CoA
dehydrogenases (42). Because short-chain methyl-branched
acyl-CoAs are also substrates for Acot9, a role in amino acid
oxidation was also proposed (5) but has not yet been tested.
To determine the potential impact of matrix thioesterase
activity on -oxidation, values of thioesterase activity (Fig. 3)
can be compared with -oxidation rates. The heart is a useful
test case because there are substantial data on palmitate oxida-
tion using [9,10-3H]palmitate, which directly assesses acyl-CoA
dehydrogenase flux. In working heart preparations, the
palmitate oxidation rate is 15 nmol/min/mg of mitochon-
drial protein (based on 1200 nmol/min/dry heart weight
and mitochondria at 2% of wet heart weight) (43–45). In
heart mitochondria, maximal thioesterase activity toward
C16:0-CoA was not much less, at 6 nmol/min/mg. If activ-
ity for C14:0-CoA, C4:0-, and C8-CoA is taken into account,
and considering that -oxidation rates are lower in other
Figure 7. Summary of findings. Mitochondrial matrix Acots reside in differ-
ent functional niches based on substrate specificity, sensitivity to CoA inhibi-
tion, and tissue-specific expression. We have localized Acot7, -9, and -13 to
the mitochondrial matrix (Fig. 1), joining Acot2 and -15 that were previously
localized to the matrix. The total height of the columns represents the approx-
imate thioesterase activity for all substrates tested, based on data from Fig. 3.
Different colors represent thioesterase activity for a particular substrate or
group of substrates, as indicated by the legend. The height of each differently
colored column (i.e. activity toward a particular substrate) represents the frac-
tional contribution of that substrate to the total thioesterase activity in mito-
chondria from the indicated tissue. Acot inside the columns, the Acot family
member that would be responsible for the thioesterase activity represented
by the color of the column (based on data from Fig. 2). For each tissue, col-
umns are shown for CoA-limiting (left grouping of columns) and CoA-replete
conditions (right grouping of columns). BAT and kidney mitochondria show
the highest total potential thioesterase activity, contributed primarily by
activity toward short-chain fatty acyl-CoAs, whereas liver mitochondria
would have very low thioesterase activity, even under CoA-limited condi-
tions. CoA was by far the strongest regulator of Acot9 and -13, and Acot2 was
minimally regulated by multiple potential allosteric regulators (see Fig. 5); a
CoA-limited condition would increase thioesterase activity for Acot7, -9, and
-13 substrates, but not for Acot2 substrates. Thus, we propose a model in
which Acot2 provides a constitutive overflow pathway for acyl-CoAs that are
likely primarily destined for -oxidation, whereas Acot7, -9, and -13 would
provide an overflow pathway that depends on the local CoA concentration.
Physiological activation of PPAR activity by fasting had only a small effect on
Acot2 activity (and protein level) (based on data from Fig. 4), despite the
substantial inducibility of Acot2 by PPAR agonists reported in the literature.
Skm, skeletal muscle.
Distinct roles of mitochondrial matrix Acots













tissues, thioesterase activity could theoretically outstrip
palmitate oxidation.
Direct evidence that a -oxidation substrate can be hydro-
lyzed to fatty acid and, thus, that -oxidation can compete with
thioesterase activity, was shown by supplying mitochondria
with [14C]palmitoylcarnitine (20 M) and then measuring
[14C]palmitate production by TLC (20, 24). Palmitate was pro-
duced at 0.03 nmol/min/mg mitochondrial protein in skeletal
muscle mitochondria (24) and 0.5 nmol/min/mg mitochon-
drial protein in heart mitochondria (20). These values are 1–2
orders of magnitude lower than the maximal thioesterase activ-
ity for palmitoyl-CoA, suggesting that matrix thioesterases
offer far less competition for -oxidation than is predicted by
maximal thioesterase activity and Km values alone. Possible
explanations for this discrepancy include unknown regulators
of the Acots and an in vivo limitation on substrate accessibility
to the Acots, either due to tight substrate channeling within
-oxidation (46) or because the Acots are located apart from
the -oxidation enzymes. Also, CoA inhibition of Acot9 and
Acot13 could remove much of the Acot competition on palmi-
tate oxidation when CoA is abundant.
Possible unique functional roles for matrix Acots in the context
of -oxidation
Evidence that Type II matrix Acots have a unique functional
role that depends on CoA abundance supports the idea these
Acots mitigate CoA limitation, as originally proposed by
Himms-Hagen and Harper (47). However, the CoA indepen-
dence of Acot2 activity implies an additional role for matrix
Acots. This role might be as a minimally regulated siphon that
removes long-chain fatty acyl-CoA from -oxidation.
An ability of matrix Acots to compete with -oxidation
implies that matrix processes can exert control over -oxida-
tion, a concept that conflicts with the generally accepted model
that the main control point for -oxidation is the entry of acti-
vated long-chain fatty acids into mitochondria by CPT1 (carni-
tine palmitoyltransferase-1) at the OMM. However, recent
experimental and modeling studies show that control of -ox-
idation can be partly or substantially taken over by the -oxi-
dation reactions themselves (6, 37). The possibility that -
oxidation enzymes exert control over -oxidation was also
suggested by measurements of -oxidation intermediates (48).
More recent modeling studies indicate that, at high C16:0-CoA
concentration, control of -oxidation shifts to the C4-C6 reac-
tions of medium-chain ketoacyl-CoA thiolase (MCKAT) (6).
This potential for overload, which could theoretically deplete
CoA and halt -oxidation (6), suggests the utility of the Acots to
mitigate gridlock at MCKAT and to prevent CoA depletion.
This model of -oxidation does not include Acot reactions (6,
37). The present study facilitates the incorporation of the
Acots.
Conclusions
We have determined that Acot7, Acot9, and Acot13 reside in
the mitochondrial matrix, joining Acot2 and Acot15. Further-
more, we report that these matrix Acots are specialized accord-
ing to substrate specificity and sensitivity to CoA inhibition
(Type II Acots). Thus, the functional relevance of Type II
matrix Acots should increase with decreasing [CoA] to ensure
that CoA does not become limiting (i.e. for -oxidation or
branched-chain amino acid catabolism). However, our study
also reveals that Acot2 is minimally influenced by factors within
the matrix, including CoA. Thus, Acot2 may be a constitutively
active matrix thioesterase and have a role beyond mitigating
CoA limitation.
Materials and methods
Details are provided in the supporting information.
Reagents
Acyl-CoA esters were purchased from Avanti Polar Lipids
and used for no longer than 2 months after dilution. Most other
reagents were purchased from Sigma–Aldrich with the excep-
tion of antibodies and recombinant Acot13.
Control and Acot2 knockout mice
10 –14-Week-old male were used in accordance with proto-
col 01307 approved by the Thomas Jefferson University Insti-
tutional Animal Care and Use Committee. C57BL/6J mice or
whole-body Acot2 knockout mice (Acot2/) were generated
from our breeding colony. The strategy used to generate mice
with floxed Acot2 alleles (Acot2fl/fl) and Acot2/ mice is
described in the legend to Fig. 3B and the supporting informa-
tion. Mice were maintained on a 12-h/12-h light/dark cycle
(lights on: 7 a.m. to 7 p.m.) and ad libitum fed a standard diet
(LabDiet 5001, Purina). Some mice were fasted overnight (7
p.m. to 9 a.m.). Mitochondria from whole-body Acot13 knock-
out mice (8) were isolated in the laboratory of Dr. David Cohen.
Expression of recombinant Acot2 in mouse liver
Adenovirus harboring mouse Acot2 cDNA or empty vector
control (2 	 109 pfu/mouse; as in Ref. 23) was diluted in saline
and then administered to mice via the tail vein, as in Ref. 23.
Liver mitochondria were isolated 7 days after injection. Local-
ization of Acot2 to mitochondria and not to cytosol was previ-
ously confirmed, as well as the appropriate substrate specificity
for Acot2 (23).
Recombinant Acot13 protein
Mouse recombinant Acot13 (generous gift from David
Cohen, Weill Cornell Medical College) was generated as
described (3). Briefly, Acot13 with an N-terminal His10 tag was
generated in Escherichia coli BL21 (De3) cells, eluted in imid-
azole, dialyzed against 20 mM sodium-phosphate buffer (pH
7.4), and then run on an SDS-polyacrylamide gel, yielding a
single band (see also Fig. 1A). The His10 tag was not removed.
Isolation of mitochondria from mouse tissues
Mice were sacrificed by cervical dislocation at 9 a.m. All
media were ice-cold, and the procedure was done on ice or at
4 °C. Protein of the final resuspended pellets was determined by
bicinchoninic assay (BCA; Life Technologies, Inc.). Detailed
protocols are provided in the supporting information.
Thioesterase activity
Thioesterase activity was measured in isolated mitochondria
(23) or recombinant Acot13 protein (3), essentially as described
(23).
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Quantitative PCR and immunoblotting
Detailed procedures as well as information about primers
and commercial antibodies is provided in the supporting infor-
mation. Custom antibodies were used to recognize Acot2,
Acot7, Acot9, Acot13, and StarD2 (generous gifts from, respec-
tively, Stefan Alexson (Karolinska Institute), Michael Wolfgang
(Johns Hopkins University), Stefan Alexson, and David Cohen
(Weill Cornell Medical College) for Acot13 and StarD2). All are
rabbit polyclonal antibodies. The anti-Acot2 antibody was
generated using Acot2 purified from rat liver as the antigen
(27). The anti-Acot7 antibody was generated using the
peptide EKKRFEEGKGRYLQMK (corresponding to amino
acids 355–370 of mouse Acot7 protein) as the antigen (26). The
anti-Acot9 antibody was generated using the peptide
CEEEELFKQGELNKS (corresponding to amino acids 225–238
of mouse ACOT9 protein Acot9) as the antigen (5). The
anti-Acot13 antibody was generated using the peptide
EKVTLVSAAPEKLIC (corresponding to amino acids 26 – 40 of
mouse Acot13 protein) as the antigen (3). The anti-StarD2 anti-
body was generated against the last 15 amino acids at the C
terminus of human StarD2 (49). Note that amino acids are
given with reference to the protein containing the mitochon-
drial targeting sequence.
Protease protection experiments
Reactions were run for 15 min, at room temperature, in a
total volume of 40 l of MAS, using 2.5 mg/ml mitochondria.
During the assay, we tested different concentrations of trypsin
(0.068, 0.102, 0.152, and 0.204 mg/ml final concentration for
each reaction) as well as proteinase K (0.01 or 0.02 mg/ml final
concentration). Digitonin was added at a final concentration
of 1, 1.25, or 1.5 g/l, and Triton was added at a final
concentration of 1 or 2%. Reactions were stopped by 10-min
incubation at room temperature with 3.25 mM phenylmeth-
ylsulfonyl fluoride.
Statistical analysis
Bar charts show the mean and S.E. Statistical analysis was
done using either a Student’s t test or analysis of variance fol-
lowed by Tukey post hoc tests, as appropriate; details are pro-
vided in the figures and figure legends. SigmaPlot was used to
perform the statistical analysis. Further details of the statistical
analysis are described throughout.
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haus, T., and Herrmann, J. M. (2018) Tom70 enhances mitochondrial
preprotein import efficiency by binding to internal targeting sequences.
J. Cell Biol. 217, 1369 –1382 CrossRef Medline
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